

Title (en)
THE USE OF PDE7 INHIBITORS FOR THE TREATMENT OF MOVEMENT DISORDERS

Title (de)
VERWENDUNG DES PDE7-HEMMERS ZUR BEHANDLUNG VON BEWEGUNGSSTÖRUNGEN

Title (fr)
UTILISATION D'INHIBITEURS PDE7 DANS LE TRAITEMENT DES TROUBLES DU

Publication
EP 2139475 A4 20120307 (EN)

Application
EP 08744515 A 20080327

Priority
• US 2008058530 W 20080327
• US 92049607 P 20070327

Abstract (en)
[origin: WO2008119057A2] A method of treating a movement abnormality associated with the pathology of a neurological movement disorder, such as Parkinson's disease or Restless Leg(s) Syndrome by administering a therapeutically effective amount of a PDE7 inhibitory agent. An aspect of the invention provides for the administration of a PDE7 inhibitory agent in conjunction with a dopamine agonist or precursor, such as levodopa. In another aspect of the invention, the PDE7 inhibitory agent may be selective for PDE7 relative to other molecular targets (i) known to be involved with the pathology of Parkinson's disease or (ii) at which other drug(s) that are therapeutically effective to treat Parkinson's disease act.

IPC 8 full level
A61K 31/435 (2006.01); **A61K 31/195** (2006.01); **A61K 31/433** (2006.01); **A61K 31/519** (2006.01); **A61K 31/527** (2006.01)

CPC (source: EP US)
A61K 31/195 (2013.01 - EP US); **A61K 31/433** (2013.01 - EP US); **A61K 31/519** (2013.01 - EP US); **A61K 31/527** (2013.01 - EP US);
A61P 21/00 (2017.12 - EP); **A61P 25/00** (2017.12 - EP); **A61P 25/14** (2017.12 - EP); **A61P 25/16** (2017.12 - EP); **A61P 25/28** (2017.12 - EP);
A61P 43/00 (2017.12 - EP)

Citation (search report)
• [X] WO 02074754 A1 20020926 - WARNER LAMBERT CO [US], et al
• [X] EP 1454897 A1 20040908 - DAIICHI SUNTORY PHARMA CO LTD [JP], et al
• [X] US 2005222138 A1 20051006 - OHHATA AKIRA [JP], et al
• [X] US 2004162294 A1 20040819 - LEBEL LORRAINE A [US], et al
• [X] US 2003069169 A1 20030410 - MACOR JOHN E [US], et al
• [X] MENNITI F S ET AL: "Phosphodiesterases in the CNS: Targets for drug development", NATURE REVIEWS. DRUG DISCOVERY, NATURE PUBLISHING GROUP, GB, vol. 5, no. 8, 1 August 2006 (2006-08-01), pages 660 - 670, XP002601485, ISSN: 1474-1784, DOI: 10.1038/NRD2058
• [A] M.A. GIEMBYCZ ET AL: "Phosphodiesterase 7 (PDE7) as a therapeutic target", DRUGS OF THE FUTURE, vol. 31, no. 3, 1 January 2006 (2006-01-01), pages 207, XP055017087, ISSN: 0377-8282, DOI: 10.1358/dof.2006.031.03.966246
• See references of WO 2008119057A2

Designated contracting state (EPC)
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

DOCDB simple family (publication)
WO 2008119057 A2 20081002; WO 2008119057 A3 20081120; AU 2008230710 A1 20081002; AU 2008230710 B2 20140410;
BR PI0809244 A2 20140923; CA 2681650 A1 20081002; CA 2681650 C 20161122; CN 101917992 A 20101215; CN 104758291 A 20150708;
CN 104758291 B 20200303; EP 2139475 A2 20100106; EP 2139475 A4 20120307; EP 2139475 B1 20141217; ES 2533206 T3 20150408;
HK 1139861 A1 20100930; JP 2010522768 A 20100708; JP 2014198718 A 20141023; JP 5580192 B2 20140827; JP 5943964 B2 20160705;
MX 2009010450 A 20091123; NZ 580413 A 20121130; RU 2009138966 A 20110510; RU 2449790 C2 20120510; US 2008260643 A1 20081023;
US 2011091388 A1 20110421; US 2019183824 A1 20190620

DOCDB simple family (application)
US 2008058530 W 20080327; AU 2008230710 A 20080327; BR PI0809244 A 20080327; CA 2681650 A 20080327;
CN 200880017058 A 20080327; CN 201510082785 A 20080327; EP 08744515 A 20080327; ES 08744515 T 20080327;
HK 10106488 A 20100705; JP 2010501232 A 20080327; JP 2014109910 A 20140528; MX 2009010450 A 20080327; NZ 58041308 A 20080327;
RU 2009138966 A 20080327; US 201816212064 A 20181206; US 5736808 A 20080327; US 97469310 A 20101221